Format

Send to

Choose Destination
Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.

Author information

1
MedImmune, Gaithersburg, Maryland, USA FalloonJ@MedImmune.com.
2
Vanderbilt University Medical Center, Nashville, Tennessee, USA.
3
Compass Research, Orlando, Florida, USA.
4
Center for Pharmaceutical Research, Kansas City, Missouri, USA.
5
Miami Research Associates, Miami, Florida, USA.
6
MedImmune, Gaithersburg, Maryland, USA.
7
MedImmune, Mountain View, California, USA.

Abstract

This is the second phase 1 study of a respiratory syncytial virus (RSV) vaccine containing RSV fusion protein (sF) adjuvanted with glucopyranosyl lipid A (GLA) in a squalene-based 2% stable emulsion (GLA-SE). In this randomized, double-blind study, 261 subjects aged ≥60 years received inactivated influenza vaccine (IIV), a vaccine containing 120 μg sF with escalating doses of GLA (1, 2.5, or 5 μg) in SE, or a vaccine containing 80 μg sF with 2.5 μg GLA in SE. Subjects receiving 120 μg sF with 2.5 or 5 μg GLA were also randomized to receive IIV or placebo. Immunity to RSV was assessed by detection of microneutralizing, anti-F immunoglobulin G, and palivizumab-competitive antibodies and F-specific gamma interferon enzyme-linked immunosorbent spot assay T-cell responses. Higher adjuvant doses increased injection site discomfort, but at the highest dose, the reactogenicity was similar to that of IIV. Significant humoral and cellular immune responses were observed. The 120 μg sF plus 5.0 μg GLA formulation resulted in the highest responses in all subjects and in older subjects. These results confirm previous observations of vaccine tolerability, safety, and immunogenicity and were used to select the 120 μg sF plus 5.0 μg GLA formulation for phase 2 evaluation. (This study has been registered at ClinicalTrials.gov under registration no. NCT02289820.).

KEYWORDS:

TLR-4 agonist; adjuvant; adult; cell-mediated immunity; respiratory syncytial virus; vaccine

PMID:
28679495
PMCID:
PMC5585697
DOI:
10.1128/CVI.00157-17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center